|
|
 |
| Àâòîðèçàöèÿ |
|
|
|
| Ïîèñê ïî óêàçàòåëÿì |
|
|
|
|
|
|
|
 |
|
|
|
| Nathanson N. (ed.), Ahmed R., Brinton M.A. — Viral Pathogenesis and Immunity |
|
|
|
| Ïðåäìåòíûé óêàçàòåëü |
 See Mean transit time
Acquired immunodeficiency syndrome (AIDS) See also Human immunodeficiency virus
Acquired immunodeficiency syndrome (AIDS), murine AIDS features 90
Acquired immunodeficiency syndrome (AIDS), neoplasms 176
Acquired immunodeficiency syndrome (AIDS), opportunistic infections 92 176
Acquired immunodeficiency syndrome (AIDS), susceptibility, AIDS resistance 164—165
Acquired immunodeficiency syndrome (AIDS), susceptibility, HLA-B57 in AIDS susceptibility 165 165t
Adenovirus, apoptosis effects 46 47
Adenovirus, downregulation of major histocompatibility complex class I expression 44—45 87—88
Adenovirus, infection course 148—149
Adenovirus, oncogenesis, E1A role 149—150 149f
Adenovirus, oncogenesis, E1B role 149—150 149f
Adenovirus, oncogenesis, rodent models 149
Adenovirus, oncogenesis, serotype activity 45t
Adenovirus, oncogenesis, tumor suppressor protein inactivation 143
Age, host, virus immunosuppression determinant 94
Age, host, virus susceptibility factors, infancy 165—167
Age, host, virus susceptibility factors, old age 167—168
AIDS See Acquired immunodeficiency syndrome
ALV See Avian leukosis virus
Antibody See Immunoglobulin
Antigen, features 57
Antigen-presenting cell (APC) See also Dendritic cell function 58
Antigen-presenting cell (APC), vaccination role 189
APC See Antigen-presenting cell
Apoptosis, adenovirus modulation 46 47
Apoptosis, assays 46
Apoptosis, features 46 47s
Apoptosis, human immunodeficiency virus induction 40 46
Apoptosis, reovirus induction 39—40
Apoptosis, Sindbis virus induction 47
Apoptosis, virus proteins in induction 46—47 47f
ASV See Avian sarcoma virus
Attenuated virus, comparative pathogenesis of virulent and attenuated viruses, host immune response 108
Attenuated virus, comparative pathogenesis of virulent and attenuated viruses, neural spread 105—106
Attenuated virus, comparative pathogenesis of virulent and attenuated viruses, portal of entry 105
Attenuated virus, comparative pathogenesis of virulent and attenuated viruses, target organ 106
Attenuated virus, comparative pathogenesis of virulent and attenuated viruses, tissue specificity 107—108
Attenuated virus, comparative pathogenesis of virulent and attenuated viruses, viremia 105
Attenuated virus, selection choice of viruses for virulence studies 104
Attenuated virus, selection cold-adapted variants 103—104
Attenuated virus, selection monoclonal antibody-resistant viruses 104
Attenuated virus, selection mutagenized viruses 104
Attenuated virus, selection temperature-sensitive mutants 103
Attenuated virus, vaccines, efficacy 190—192
Attenuated virus, vaccines, poliovirus vaccine attenuation 9—10 100 193t
Attenuated virus, vaccines, safety 192—193 193t
Attenuated virus, vaccines, tropism 190 192t
Autoimmune disease, molecular mimicry by viruses 78—80
Avian influenza virus, blocking of infection 43f
Avian influenza virus, susceptibility factors 162
Avian influenza virus, tropism variability 35t 36
Avian leukosis virus (ALV), blocking of infection 43f
Avian leukosis virus (ALV), oncogenesis 137—138
Avian leukosis virus (ALV), receptor saturation 42
Avian leukosis virus (ALV), susceptibility factors 162
Avian sarcoma virus (ASV), oncogenesis 137—138
Avian sarcoma virus (ASV), receptor saturation 42
B cell, Epstein — Barr virus infection 150
B cell, immune response overview 48f 57 59f
B cell, immunoglobulin production pathway 58
B cell, kinetics of humoral response 62—63
B cell, maturation 56
B cell, mucosal immune response 67—68
B cell, protection against reinfection 67
B cell, specificity of response 57—58
Bcl-2; apoptosis inhibition 47
Bcl-2; Sindbis virus susceptibility role 166
Bgpl, mouse hepatitis virus susceptibility role 162
Blood, shedding of viruses 22
Bunyavirus, virulence, genetic determinants 107f 109
Burkitt's lymphoma See Epstein — Barr virus
Canine distemper virus (CDV), immunosuppression induction 90 90f
Carbohydrate, viral receptors 29f
CD4 lymphocyte See also T cell
CD4 lymphocyte, cell mediated immunopathology effector function 71—72 73
CD4 lymphocyte, cytokine production 65
CD4 lymphocyte, effector functions 65
CD4 lymphocyte, function 58
CD4 lymphocyte, helper cell subsets 58 60
CD4 lymphocyte, human immunodeficiency virus targeting 27—28 44f 83 92—93 93f 121 173—174
CD4 lymphocyte, immunopathology role 75t
CD4 lymphocyte, SU, CD4 binding 171 172f 177
CD4 lymphocyte, virus effects on helper cell balance 60
CD8 lymphocyte See also T cell assays; 64t
CD8 lymphocyte, cell-mediated immunopathology, clinical disease 73—76
CD8 lymphocyte, cell-mediated immunopathology, experimental examples 72—73
CD8 lymphocyte, cell-mediated immunopathology, mechanisms 70—72
CD8 lymphocyte, cytokine production 71
CD8 lymphocyte, effector functions 65
CD8 lymphocyte, function 58
CD8 lymphocyte, hepatitis B virus clearance 201—202
CD8 lymphocyte, human immunodeficiency virus effects 182 183
CD8 lymphocyte, kinetics of virus response 65—66
CD8 lymphocyte, lymphocytic choriomeningitis virus induction of tolerance 85—86
CD8 lymphocyte, rabies virus response 200
CDV See Canine distemper virus
Cell cycle, virus regulation 45
Cervical cancer See Human papillomavirus
Chemokine receptors, CCR5 mutations, AIDS resistance 164—165
Chemokine receptors, CCR5 mutations, human immunodeficiency virus infection resistance 163t 164 182
Chemokine receptors, human immunodeficiency virus utilization, apoptosis induction 46
Chemokine receptors, human immunodeficiency virus utilization, receptor types in binding 171
Chemokine receptors, human immunodeficiency virus utilization, signaling 40
Chemokine receptors, human immunodeficiency virus utilization, strain variations 171
Chemokine receptors, mutations and human immunodeficiency, virus mfection resistance 164 182 183
Chromium-51 release assay, cellular immunity 63f 64
Clearance, virus 18 19
CMV See Cytomegalovirus
Complement, cascade 57f
Complement, Clq binding by antibodies 62 87
Complement, host defense 55—56
Complement, viral interference of cascade 87
Conjunctiva, virus entry 14
CREB, transcription regulation by viruses 41
Cytomegalovirus (CMV), latency 119—120
Cytomegalovirus (CMV), transcription regulation 41
Cytotoxic T lymphocyte See CD8 lymphocyte
Dendritic cell, function 56—57 58
Dendritic cell, human immunodeficiency virus infection 173
Dendritic cell, lymphocytic choriomeningitis virus targeting 83—84
Dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS), antibody-mediated immunopathology 77—78 78f
Dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS), epidemiology 77—78
Dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS), transmission 77
DHF/DSS See Dengue hemorrhagic fever/dengue shock syndrome
DNA vaccine, administration 196
DNA vaccine, advantages 196
DNA vaccine, human immunodeficiency virus 207
DNA vaccine, promoters 195
DNA vaccine, protein trafficking 195—196
DNA vaccine, simian immunodeficiency virus 208f
Dulbecco, M. 7
E1A; downregulation of major histocompatibility complex 45
E1A; oncogenesis role 149—150
E1B, oncogenesis role 149—150
E3; trapping of major histocompatibility complex class I molecules 44—45 87—88
E5; oncogenesis role 147
E6; oncogenesis role 147—148
E7; oncogenesis role 147—148
EBNA-1, oncogenesis role 150—151
Ebola virus, necrosis induction 46
EBV See Epstein — Barr virus
Ectromelia virus, spread in mouse 9f
Ehrlich, Paul 7
ELISA See Enzyme-linked immunosorbent assay
ELISPOT, antibody assay 61 63
ELISPOT, cellular immunity assay 65
Enzyme-linked immunosorbent assay (ELISA), antibody assay 60
Epithelial cell, polarization and virus infection 17
Epstein — Barr virus (EBV), B cell infection 150
| Epstein — Barr virus (EBV), epithelial cell infection 150
Epstein — Barr virus (EBV), infection course 150
Epstein — Barr virus (EBV), latency 119—120 150
Epstein — Barr virus (EBV), oncogenesis 151f
Epstein — Barr virus (EBV), oncogenesis, Burkitt's lymphoma 151—152
Epstein — Barr virus (EBV), oncogenesis, EBNA-1 role 150—151
Epstein — Barr virus (EBV), oncogenesis, genes 152t
Epstein — Barr virus (EBV), oncogenesis, immunosuppression effects 151
Epstein — Barr virus (EBV), oncogenesis, LMP1 role 150—151
Equine infectious anemia virus, persistence mechanisms 122 123t
Exocytosis, virions 38—39
FACS See Fluorescence-activated cell sorting
Fenner, Frank 7
Finlay, Carlos 6
Fluorescence-activated cell sorting (FACS), cellular immunity assay 64—65
Flv, flavivirus susceptibility role 160—161
Foot-and-mouth disease, history of study 5—6
Fracastoro, Girolamo 3
Fv-1; murine leukemia virus susceptibility role 161—162
Gastrointestinal tract, acid lability of viruses 33
Gastrointestinal tract, entry of viruses 15—16 15t 16f
Gastrointestinal tract, shedding of viruses 21
Glycoprotein viral receptors 27f
HA See Hemagglutinin
HBV See Hepatitis B virus
Hemagglutinin (HA), proteolytic activation 32—33 33f
Hemagglutinin (HA), structure 30f
Henle — Koch postulates 5 5s
Heparan, cellular virus receptor 28 29f
Hepatitis A virus, perpetuation 23 23f
Hepatitis B virus (HBV), age effects on susceptibility 167
Hepatitis B virus (HBV), CD8 cell role in clearance 201—202
Hepatitis B virus (HBV), cell-mediated immunopathology 73—76
Hepatitis B virus (HBV), clearance 201 f
Hepatitis B virus (HBV), course of infection 75f 201f
Hepatitis B virus (HBV), cytokines in clearance 65f
Hepatitis B virus (HBV), eradication 24
Hepatitis B virus (HBV), humoral immunity 76
Hepatitis B virus (HBV), immune globulin protection 202 202f 202t
Hepatitis B virus (HBV), mouse model 76s
Hepatitis B virus (HBV), myelin basic protein mimicry 79
Hepatitis B virus (HBV), pathogenesis 200—201 201f
Hepatitis B virus (HBV), persistence 114 117—118
Hepatitis B virus (HBV), vaccination, active immunization of infants 203 203f
Hepatitis B virus (HBV), vaccination, historical perspective 203
Hepatitis B virus (HBV), vaccination, recombinant protein vaccine 194 202
Herpes simplex virus (HSV), cellular receptors 26—27 28
Herpes simplex virus (HSV), complement cascade interference 87 87f 87t
Herpes simplex virus (HSV), Fc receptors as virulence factors 112—113 112f
Herpes simplex virus (HSV), latency 119—120 120f 124—126
Herpes simplex virus (HSV), latency associated transcripts 125
Herpes simplex virus (HSV), life cycle 125f
Herpes simplex virus (HSV), reactivation factors 125—126
Herpes simplex virus (HSV), serotypes 124
HHV-8 See Human herpesvirus 8
Historical perspective, virus research, prospects 11
Historical perspective, virus research; 1900—1950 6—7
Historical perspective, virus research; 1950—1975 7—8
Historical perspective, virus research; 1975 — present 9—11
Historical perspective, virus research; pre-1900s 3—6
HIV See Human immunodeficiency virus
HPV See Human papillomavirus
hsv See Herpes simplex virus
HTLV-I See Human T-cell lymphotrophic virus type I
Human herpesvirus 8 (HHV-8), cell cycle regulation 45
Human herpesvirus 8 (HHV-8), Kaposi's sarcoma role, discovery 152—153 153t
Human herpesvirus 8 (HHV-8), Kaposi's sarcoma role, pathogenesis 153—154 154f 154t
Human immunodeficiency virus HIV) See also Acquired immunodeficiency syndrome
Human immunodeficiency virus HIV), acute infection 175—176
Human immunodeficiency virus HIV), apoptosis induction 40 46
Human immunodeficiency virus HIV), blood to tissue spread 20
Human immunodeficiency virus HIV), CD4 cell, counts 175—176
Human immunodeficiency virus HIV), CD4 cell, depletion and immunosuppression 182
Human immunodeficiency virus HIV), CD4 cell, targeting 27—28 44f 83 92—93 93f 121 173—174
Human immunodeficiency virus HIV), CD4 cell, turnover 178—179
Human immunodeficiency virus HIV), CD8 cell effects 182 183
Human immunodeficiency virus HIV), cell cycle regulation 45
Human immunodeficiency virus HIV), cell killing in vitro 173—174
Human immunodeficiency virus HIV), cell killing in vivo 174
Human immunodeficiency virus HIV), cellular immune response 177—178 178f
Human immunodeficiency virus HIV), cellular receptors 172f
Human immunodeficiency virus HIV), cellular receptors, CD4; 26, 26f 28 28f 92 170 171
Human immunodeficiency virus HIV), cellular receptors, chemokine receptors 26f 40 171
Human immunodeficiency virus HIV), cellular receptors, mutations and susceptibility 183t
Human immunodeficiency virus HIV), cellular receptors, saturation 42
Human immunodeficiency virus HIV), clades 182 206
Human immunodeficiency virus HIV), comparative pathogenesis of virulent and attenuated viruses 108
Human immunodeficiency virus HIV), control 183
Human immunodeficiency virus HIV), dendritic cell infection 173
Human immunodeficiency virus HIV), entry 172f
Human immunodeficiency virus HIV), entry, cells 29—30
Human immunodeficiency virus HIV), entry, portal 174
Human immunodeficiency virus HIV), genome 171f
Human immunodeficiency virus HIV), highly-active antiretroviral therapy response 178—179 180f
Human immunodeficiency virus HIV), humoral immune response 177 177f
Human immunodeficiency virus HIV), immunogenic proteins 176—177
Human immunodeficiency virus HIV), immunosuppression mechanisms 92—93 182
Human immunodeficiency virus HIV), kinetics of infection 179f 204f
Human immunodeficiency virus HIV), latency 176
Human immunodeficiency virus HIV), lentivirus features 170—171
Human immunodeficiency virus HIV), molecular mimicry 80t
Human immunodeficiency virus HIV), mutation, evolution during persistent infection 180
Human immunodeficiency virus HIV), mutation, immunological escape mutants 182
Human immunodeficiency virus HIV), mutation, phenotypes 180
Human immunodeficiency virus HIV), mutation, rates 180
Human immunodeficiency virus HIV), Nef downregulation of major histocompatibility complex 44
Human immunodeficiency virus HIV), nonpathogenic infection 180—182
Human immunodeficiency virus HIV), passage 103
Human immunodeficiency virus HIV), perpetuation 23
Human immunodeficiency virus HIV), persistence and turnover 178
Human immunodeficiency virus HIV), phenotype by stage of infection 181f 181t
Human immunodeficiency virus HIV), prospects for study 11
Human immunodeficiency virus HIV), replication 173f
Human immunodeficiency virus HIV), simian immunodeficiency virus chimera, tropism 36—37 36f
Human immunodeficiency virus HIV), simian immunodeficiency virus chimera, vaccination studies 204—206 208f
Human immunodeficiency virus HIV), species susceptibility 171
Human immunodeficiency virus HIV), spread of infection 174
Human immunodeficiency virus HIV), susceptibility, AIDS resistance 164—165
Human immunodeficiency virus HIV), susceptibility, HLA-B57 in AIDS susceptibility 165 165t
Human immunodeficiency virus HIV), susceptibility, infection resistance 164 182 183
Human immunodeficiency virus HIV), transmission 174 183
Human immunodeficiency virus HIV), tropism among isolaes of same virus 108t
Human immunodeficiency virus HIV), vaccination, attenuated virus 203—204
Human immunodeficiency virus HIV), vaccination, cellular immunity induction 206
Human immunodeficiency virus HIV), vaccination, challenges 203—204
Human immunodeficiency virus HIV), vaccination, cross-clade immunity 206—207 207f 207t
Human immunodeficiency virus HIV), vaccination, DNA vaccine 207
Human immunodeficiency virus HIV), vaccination, historical perspective 203—204
Human immunodeficiency virus HIV), vaccination, immunologic correlates of protection 205—206
Human immunodeficiency virus HIV), vaccination, macaque model 204
Human immunodeficiency virus HIV), vaccination, neutralizing antibody induction 206
Human immunodeficiency virus HIV), vaccination, partial immunity protection 204
Human immunodeficiency virus HIV), vaccination, recombinant gp120 203 207
Human immunodeficiency virus HIV), vaccination, viremia and viral set point 174—175 175f 175t 177f 205f
Human papillomavirus (HPV), E2 mimicry of insulin receptor 80t
Human papillomavirus (HPV), genome 145
Human papillomavirus (HPV), oncogenesis, animal models 148 158
Human papillomavirus (HPV), oncogenesis, E5 role 147
Human papillomavirus (HPV), oncogenesis, E6 role 147—148 148f
Human papillomavirus (HPV), oncogenesis, E7 role 147—148 148f
Human papillomavirus (HPV), oncogenesis, immunologic factors 148 148f
Human papillomavirus (HPV), oncogenesis, serotypes 145t
Human papillomavirus (HPV), oncogenesis, transcripts by cancer type 145—146
Human papillomavirus (HPV), oncogenesis, transgenic mouse studies 145t
Human papillomavirus (HPV), oncogenesis, tumor suppressor protein inactivation 143
Human papillomavirus (HPV), receptors 146
Human papillomavirus (HPV), replication 145—147
Human papillomavirus (HPV), serotypes 145t
Human papillomavirus (HPV), transcriptional control of tropism 34 35 35f 146f
Human papillomavirus (HPV), types and virulence 144—145
|
|
|
| Ðåêëàìà |
|
|
|
|
|
|
|
|
Î ïðîåêòå